Outlook Therapeutics Trend 2026

Outlook Therapeutics is a clinical-stage biopharmaceutical company pioneering treatments for retinal diseases. It develops innovative ophthalmic formulations, notably its lead candidate, ONS-5010, a bevacizumab-based therapy for wet age-related macular degeneration (AMD). Administered via intravitreal injection, it targets vision loss by inhibiting abnormal blood vessel growth. Patients with AMD, diabetic macular edema, and retinal vein occlusion may benefit from this potential therapy, offering a more accessible treatment option.